ADC Therapeutics ADCT
NYSE ADCT
$0.98 +0.02 (+2.38%)
As of: Aug 21, 2026 · 9:35 AM EDT

ADC Therapeutics (ADCT) Revenue (2021 - 2026)

ADC Therapeutics (ADCT) posted Revenue of $20.9 million for Q1 2026, up 26.93% sequentially from $16.4 million in Q3 2025, and down 9.47% YoY from $23.0 million in Q1 2025.

ADC Therapeutics (ADCT) Revenue (2021 - 2026) Analysis & Trends

ADC Therapeutics has reported Revenue for 6 years, with the latest figure at $20.9 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Vertex Pharmaceuticals 138.04 Bn 130.19 Bn 2.84 Bn 3.33 Bn
2 Regeneron Pharmaceuticals 85.58 Bn 77.59 Bn 3.93 Bn 4.29 Bn
3 Argenx Se 64.52 Bn 59.34 Bn 1.37 Bn 1.52 Bn
4 Moderna 56.52 Bn 51.38 Bn 52.00 Mn 145.00 Mn
5 BeOne Medicines 42.04 Bn 36.94 Bn 1.53 Bn 1.71 Bn
6 Alnylam Pharmaceuticals 30.67 Bn 27.36 Bn 992.69 Mn 1.29 Bn
7 Insmed 27.27 Bn 26.11 Bn 358.27 Mn 425.49 Mn
8 BioNTech SE 27.14 Bn 8.75 Bn 668.28 Mn 1.06 Bn
9 Royalty Pharma 27.12 Bn 26.28 Bn - 674.14 Mn
10 ADC Therapeutics 151.40 Mn -67.70 Mn 17.14 Mn 19.25 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 19.25 Mn
Mar 31, 2026 20.85 Mn
Sep 30, 2025 16.43 Mn
Jun 30, 2025 18.84 Mn
Mar 31, 2025 23.03 Mn
Sep 30, 2024 18.46 Mn
Jun 30, 2024 17.41 Mn
Mar 31, 2024 18.05 Mn
Sep 30, 2023 14.49 Mn
Jun 30, 2023 19.28 Mn
Mar 31, 2023 18.99 Mn
Sep 30, 2022 76.32 Mn
Jun 30, 2022 17.29 Mn
Mar 31, 2022 46.50 Mn
Sep 30, 2021 13.15 Mn
Jun 30, 2021 3.76 Mn